News
Media
Conferences
Publications
CME/CE
Resources
Subscribe
About
Partnerships

|Articles|August 3, 2011

Intrauterine Contraceptive Devices

Author(s)Ashraf Fouda, MD

Newsletter

Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.

Related Content

Image credit: Society of Family Planning

Society of Family Planning issues first guidance on deep and nonpalpable contraceptive implant removal

ByJoshua Fitch, Senior Editor

September 10th 2026

A recap of top FDA & regulatory news from August 2026

A recap of top FDA & regulatory news from August 2026

ByContemporary OB/GYN Staff

September 1st 2026

Jeffrey Jensen, MD, contextualizes contraceptive efficacy in modern trials

ByJoshua Fitch, Senior Editor ,Jeffrey Jensen, MD, MPH

August 4th 2026

Jeffrey Jensen, MD, MPH, welcomes the newly approved Gwyn Lo contraceptive patch as an expanded, low-estrogen option for patients seeking a once-weekly method.

Jeffrey Jensen, MD, reacts to FDA approval of new contraception patch, Gwyn Lo

ByJoshua Fitch, Senior Editor ,Jeffrey Jensen, MD, MPH

August 3rd 2026

FDA approves norelgestromin and ethinyl estradiol transdermal patch for contraception

FDA approves norelgestromin and ethinyl estradiol transdermal patch for contraception

ByJoshua Fitch, Senior Editor

July 29th 2026

Latest CME

Join Us at The Pathology Meeting in Las Vegas

In-Person + Virtual Event

Join Us at The Pathology Meeting in Las Vegas

October 5, 2026

Join Us at The Pathology Meeting in Las Vegas

In-Person + Virtual Event

Join Us at The Pathology Meeting in Las Vegas

October 4-5, 2026

SimulatEd™: A Roadmap to Personalized Care Plans and Shared Decision-Making in Low-Grade Serous Ovarian Cancer

Case-based Simulation

SimulatEd™: A Roadmap to Personalized Care Plans and Shared Decision-Making in Low-Grade Serous Ovarian Cancer

Rachel N. Grisham, MD

Trending on Contemporary OB/GYN

Society of Family Planning issues first guidance on deep and nonpalpable contraceptive implant removal

Amber Watters, MD, on emergency preparedness and building a version program

Certolizumab pegol receives FDA BTD for adverse pregnancy outcomes in APS

Phase 3 LUNA study: atogepant reduces menstrual migraine days vs. placebo

PMOS Awareness Month: Watch our expert panel discussion on PMOS